PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/505, A61P 3/06 — A1

(11) International Publication Number: WO 00/45819

(43) International Publication Date: 10 August 2000 (10.08.00)

(21) International Application Number: PCT/GB00/00285

(22) International Filing Date: 1 February 2000 (01.02.00)

(30) Priority Data:

9902590.0	6 February 1999 (06.02.99)	GB
9921062.7	8 September 1999 (08.09.99)	GB

(71) Applicant *(for all designated States except US)*: AS-TRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: RAZA, Ali [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: BRYANT, Tracey; Global Intellectual Property, Patents, AstraZeneca UK Limited, Mereside, Alderley Park, Macclesfield, Chesire SK10 4TG (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: USE OF CHOLESTEROL–LOWERING AGENT

(57) Abstract

The invention concerns the use of particular oral dosages or dosage ranges of the compound (E) –7 –[4 –(4 –fluorophenyl) –6 –isopropyl –2 –[methyl(methylsulfonyl)amino]pyrimidin –5 –yl] –(3R,5S) –3,5 –dihydr oxyhept –6 –enoic acid or a pharmaceutically acceptable salt thereof, to alter beneficially lipid levels or lipid ratios in a human patient in need thereof, as well as pharmaceutical compositions of said compound or salts adapted for oral administration which comprise such dosages, and methods of preparation thereof.